Adma Biologics (ADMA) Other Operating Expenses (2011 - 2025)

Adma Biologics has reported Other Operating Expenses for 13 years, with the latest figure at $1.2 million in Q4 2025.

• For the quarter ending Q4 2025, Other Operating Expenses fell 9.6% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2025 stood at $5.0 million (up 7.53% YoY), and the FY2025 full-year result was $5.0 million, up 7.49% from the prior year.
• Other Operating Expenses for Q4 2025 stood at $1.2 million, down from $1.3 million in the prior quarter.
• The five-year high for Other Operating Expenses was $5.3 million in Q4 2022, with the low at $646000.0 in Q3 2023.
• Historically, Other Operating Expenses has averaged $2.3 million across 5 years, with a median of $1.4 million in 2023.
• Annual changes were most pronounced in 2021 — Other Operating Expenses surged 110.58% — and 2023, when it plunged 87.18%.
• Adma Biologics' Other Operating Expenses stood at $4.3 million in 2021, then climbed by 23.16% to $5.3 million in 2022, then slumped by 83.44% to $872000.0 in 2023, then surged by 49.31% to $1.3 million in 2024, then retreated by 9.6% to $1.2 million in 2025.
• The last three Other Operating Expenses figures came in at $1.2 million (Q4 2025), $1.3 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.